100 Or More Amino Acid Residues In The Peptide Chain Patents (Class 514/21.2)
-
Patent number: 8987204Abstract: It is an object of the present invention to provide a bone regeneration agent and a bone supplementation formulation, in which a supplementation material itself is capable of promoting bone regeneration. The present invention provides a bone regeneration agent which comprises a gelatin having an amino acid sequence derived from a partial amino acid sequence of collagen.Type: GrantFiled: September 3, 2010Date of Patent: March 24, 2015Assignee: FUJIFILM CoporationInventors: Takahiro Hiratsuka, Shouji Ooya, Ichiro Nishimura
-
Patent number: 8987210Abstract: This application is directed to chemokine-immunoglobulin fusion polypeptides and chemokine-polymer conjugates. The fusion polypeptides and conjugates can be used for treating chemokine receptor-mediated disorders and modulating inflammation, inflammatory cell motility, cancer cell motility, or cancer cell survival.Type: GrantFiled: August 8, 2013Date of Patent: March 24, 2015Assignee: Jyant Technologies, Inc.Inventor: James W. Lillard, Jr.
-
Patent number: 8987211Abstract: Fusion proteins that contain the fusion of (i) a peptide of less than 100 amino acids comprising a first amino acid sequence comprising AASSG (SEQ ID NO: 1) and a second amino acid sequence comprising XAGXDXXTEXPXS (SEQ ID NO: 2), wherein X designates any amino acid, and (ii) a protein transduction domain (PTD) are provided, along with pharmaceutical compositions containing the fusion protein. The proteins can be used to treat Huntington's disease.Type: GrantFiled: April 12, 2012Date of Patent: March 24, 2015Assignees: Centre National de la Recherche Scientifique (CNRS), Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Montpellier 2 Sciences et TechniquesInventors: Florence Maschat, Marie-Laure Parmentier, Nathalie Bonneaud, Yoan Arribat
-
Publication number: 20150079083Abstract: The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an agent that provides alpha B-crystallin activity, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease. In some embodiments, the methods of the invention comprise administering to a subject having a pre-existing inflammatory disease condition, an effective amount of alpha B-crystallin protein, to suppress or prevent relapses of the disease.Type: ApplicationFiled: July 7, 2014Publication date: March 19, 2015Inventors: Lawrence Steinman, Shalina Sheryl Ousman, William H. Robinson
-
Publication number: 20150079012Abstract: Provided herein relates to silk fibroin-based compositions comprising non-hydrolyzed silk fibroin and a humectant agent and methods of making the same. In some embodiments, the silk fibroin-based compositions can be formulated for personal care products, e.g., but not limited to, cosmetic products, skin care products, body care products, and/or hair products. In some embodiments, the silk fibroin-based compositions can be formulated for food applications.Type: ApplicationFiled: April 22, 2013Publication date: March 19, 2015Inventors: Evangelia Bellas, Amanda Baryshyan, Lindsay Wray, David L. Kaplan
-
Patent number: 8980841Abstract: A method for treating a disease, particularly asthma and anaphylactic shock, comprises administering to a subject in need thereof an effective amount of an EC-SOD protein or a vector having a polynucleotide encoding thereof.Type: GrantFiled: July 7, 2014Date of Patent: March 17, 2015Assignee: Catholic University of Korea Industry-Academic Cooperation FoundationInventors: Dong Heon Shin, Tae Yoon Kim
-
Patent number: 8980826Abstract: The present invention relates to a method of promoting bronchodilation by administration of streptolysin O to a subject in need thereof.Type: GrantFiled: February 27, 2013Date of Patent: March 17, 2015Assignee: Beech Tree Labs, Inc.Inventor: John McMichael
-
Patent number: 8981057Abstract: The invention relates to the fields of molecular biology, medicine, virology and vaccine development. Because the different forms of the presently available vaccines all have their specific drawbacks, there is a need for alternative vaccine strategies. The current invention provides means and methods for such alternative vaccine strategies.Type: GrantFiled: March 7, 2011Date of Patent: March 17, 2015Assignee: Academisch Medisch Centrum Bij De Universiteit Van AmsterdamInventor: Rogier Willem Sanders
-
Publication number: 20150071914Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.Type: ApplicationFiled: May 29, 2014Publication date: March 12, 2015Applicant: Bristol-Myers Squibb CompanyInventors: Robert James PEACH, Joseph Naemura, Peter S. Linsley, Jurgen Bajorath
-
Publication number: 20150071906Abstract: Compositions, methods, strategies, kits, and systems for the supercharged protein-mediated delivery of functional effector proteins into cells in vivo, ex vivo, or in vitro are provided. Compositions, methods, strategies, kits, and systems for delivery of funcational effector proteins using cationic lipids and cationic polymers are also provided. Functional effector proteins include, without limitation, transcriptional modulators (e.g., repressors or activators), recombinases, nucleases (e.g., RNA-programmable nucleases, such as Cas9 proteins; TALE nuclease, and zinc finger nucleases), deaminases, and other gene modifying/editing enzymes. Functional effector proteins include TALE effector proteins, e.g., TALE transcriptional activators and repressors, as well as TALE nucleases.Type: ApplicationFiled: August 18, 2014Publication date: March 12, 2015Applicant: President and Fellows of Harvard CollegeInventors: David R. Liu, John Anthony Zuris, David B. Thompson
-
Publication number: 20150072936Abstract: The present invention provides methods for promoting wound healing and/or reducing scar formation, by administering to an individual in need thereof one or more of the heat shock protein 20-derived polypeptides disclosed herein.Type: ApplicationFiled: May 21, 2014Publication date: March 12, 2015Inventors: Colleen M. Brophy, Alyssa Panitch, Catherine Parmiter, Elizabeth J. Furnish, Padmini Komalavilas
-
Publication number: 20150072019Abstract: The present invention relates generally to 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl)-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of X-linked hypophosphatemic rickets (XLH), autosomal dominant hypophosphatemia rickets (ADHR), autosomal recessive hypophosphatemic rickets (ARHR), tumor-induced osteomalacia, post-renal transplant hypophosphatemia, epidermal nevus syndrome, osteoglophonic dysplasia or McCune-Albright syndrome.Type: ApplicationFiled: March 29, 2013Publication date: March 12, 2015Inventors: Michaela Kneissel, Vito Gaugnano, Diana Graus Porta, Simon Wöhrle
-
Publication number: 20150071903Abstract: Compositions, methods, strategies, kits, and systems for the supercharged protein-mediated delivery of functional effector proteins into cells in vivo, ex vivo, or in vitro are provided. Compositions, methods, strategies, kits, and systems for delivery of functional effector proteins using cationic lipids and cationic polymers are also provided. Functional effector proteins include, without limitation, transcriptional modulators (e.g., repressors or activators), recombinases, nucleases (e.g., RNA-programmable nucleases, such as Cas9 proteins; TALE nuclease, and zinc finger nucleases), deaminases, and other gene modifying/editing enzymes. Functional effector proteins include TALE effector proteins, e.g., TALE transcriptional activators and repressors, as well as TALE nucleases.Type: ApplicationFiled: August 18, 2014Publication date: March 12, 2015Applicant: President and Fellows of Harvard CollegeInventors: David R. Liu, John Anthony Zuris, David B. Thompson
-
Patent number: 8975230Abstract: Described herein are methods and compositions related to the discovery that the Follistatin-like 1 protein (Fstl-1) has metabolic and cardioprotective effects in vivo. Fstl-1 and portions and derivatives or variants thereof can be used to treat or prevent metabolic diseases or disorders and to treat or prevent cardiac damage caused by interrupted cardiac muscle blood supply.Type: GrantFiled: October 5, 2012Date of Patent: March 10, 2015Assignee: Trustees of Boston UniversityInventors: Kenneth Walsh, Yuichi Oshima, Noriyuki Ouchi
-
Publication number: 20150064188Abstract: Isolated polypeptides comprising or consisting essentially of specific structural motifs (e.g., three ?-sheets and two ?-helices) are provided, wherein the polypeptides exhibit at least one cell signaling and/or other non-canonical activity of biological relevance. Also provided are polynucleotides encoding such polypeptides, binding agents that bind such polypeptides, analogs, variants and fragments of such polypeptides, etc., as well as compositions and methods of identifying and using any of the foregoing.Type: ApplicationFiled: August 6, 2014Publication date: March 5, 2015Inventor: Leslie Ann Greene
-
Patent number: 8968747Abstract: Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.Type: GrantFiled: April 16, 2013Date of Patent: March 3, 2015Assignee: Allergan, Inc.Inventors: Catherine C. Turkel, Sheena K. Aurora, Mitchell F. Brin
-
Patent number: 8969292Abstract: Leptin muteins, in particular leptin antagonists, with increased binding affinity to leptin receptor are provided. These compounds as well as pharmaceutical composition comprising them are useful for the treatment of any disorder in which a non-desirable or deleterious activity of endogenous leptin or an altered innate immune response is implicated.Type: GrantFiled: April 17, 2011Date of Patent: March 3, 2015Assignees: The Medical Research, Infrastructure, and Health Services Fund of the Tel-Aviv Medical Center, Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Inventors: Arieh Gertler, Eran Elinav, Zamir Halpern
-
Publication number: 20150056231Abstract: Recombinant papaya mosaic virus (PapMV) coat proteins comprising one or more antigenic peptides derived from an influenza virus antigen, such as from the M2e peptide, fused at a position within a predicted random coil within 13 amino acids of the N-terminus of the coat protein, uses thereof to prepare virus-like particles (VLPs), and uses of the VLPs in influenza vaccines.Type: ApplicationFiled: February 19, 2013Publication date: February 26, 2015Inventors: Denis Leclerc, Nathalie Majeau
-
Publication number: 20150056163Abstract: The present invention relates to methods for preventing or treating Human Immunodeficiency Virus (HIV) infection, inflammatory conditions, and graft-versus-host-disease (GVHD) in a subject. Therapeutic compositions of the present invention comprise Leukocidin E (LukE) and/or D proteins or polypeptides. The invention further relates to methods of treating Staphylococcus aureus infection by administering a composition comprising a CCR5 antagonist or any molecule that blocks LukE/D interaction with CCR5+ cells in an amount effective to treat the S. aureus infection in the subject.Type: ApplicationFiled: August 25, 2014Publication date: February 26, 2015Inventors: Victor J. Torres, Derya Unutmaz, Francis Alonzo, III
-
Publication number: 20150051158Abstract: The present disclosure relates to CTLA4 proteins and uses of such proteins, for example to treat diseases associated with the dysregulation of immune responses.Type: ApplicationFiled: October 27, 2014Publication date: February 19, 2015Inventors: Yoshiko AKAMATSU, Veronica Juan, Robert B. Dubridge
-
Publication number: 20150050215Abstract: The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related tauopathies. The present invention also provides a method for a prophylactic and therapeutic treatment of Alzheimer's disease and other neurodegenerative tauopathies. This method entails the injection of antibodies and/or peptide vaccines that elicits an immune response directed to pathological tau proteins and tau deposits in the brains of patients. Suitable vaccines represent a tau peptide carrying one or more of the tau therapeutic epitopes provided herein.Type: ApplicationFiled: September 14, 2012Publication date: February 19, 2015Applicant: Axon Neuroscience SEInventors: Michal Novak, Eva Kontseková, Branislav Kovácech, Norbert Zilka
-
Publication number: 20150051136Abstract: The present disclosure provides a method for recombinant production of human sRAGE in mammalian cells, as well as a human sRAGE having a mammalian post-translational modification and compositions thereof. The present disclosure also provides a method of treating a vascular disease, injury, or inflammation in a mammal by administering to a mammal with a vascular disease, injury, or inflammation a composition comprising human sRAGE having a mammalian post-translational modification, thereby treating the vascular disease, injury, or inflammation in the mammal.Type: ApplicationFiled: January 3, 2013Publication date: February 19, 2015Inventors: Li Lin, Sungha Park, Wen Wei, Rui-Ping Xiao, Mark I. Talan, Edward G. Lakatta
-
Patent number: 8957028Abstract: The invention, in some aspects, relates to compositions and methods for altering cell activity and function. The invention also relates, in part, to the use of light-activated ion pumps (LAIPs) such as a light-activated ion pump polypeptide that when expressed in an excitable cell and contacted with a red light silences the excitable cell, wherein the polypeptide sequence of the light-activated ion pump comprises a wild-type or modified halomicrobium or haloarcula halorhodopsin polypeptide sequence.Type: GrantFiled: November 14, 2011Date of Patent: February 17, 2015Assignee: Massachusetts Institute of TechnologyInventors: Amy Chuong, Nathan Klapoetke, Brian Yichiun Chow, Edward Boyden, Xue Han
-
Publication number: 20150044145Abstract: The present invention provides materials and methods for inducing ion secretion and/or for treating cystic fibrosis. In one embodiment, the composition comprises glucose and/or a non-metabolizable glucose analog and/or non-structural protein (NSP4), a NSP4 peptide, or a NSP4 toxoid as the active ingredient, formulated with pharmaceutically-acceptable carriers. In a preferred embodiment, the composition is in a form of an aerosol preparation for intranasal and/or pulmonary administration, and is used to stimulate chloride and fluid secretion in nasal, tracheal and/or bronchial epithelium.Type: ApplicationFiled: March 15, 2013Publication date: February 12, 2015Inventors: Sadasivan Vidyasagar, Paul Okunieff, Sreekala Prabhakaran, Lurong Zhang
-
Publication number: 20150045283Abstract: The present invention provides novel PAR lderived cytoprotective oligopeptides or polypeptides which typically contain at least the first 4 N-terminal residues that are substantially identical to the corresponding N-terminal residues of Met1-Arg46 deleted human PAR 1 sequence. These cytoprotective oligopeptides or polypeptides are capable of activating PAR 1 and promoting PAR 1 cytoprotective signaling activities. The invention also provides engineered cells or transgenic non-human animals which harbor in their genome an altered PAR 1 gene that is resistant to cleavage at Arg41 and/or Arg46 residues. Additionally provided in the invention are methods of screening candidate compounds to identity additional cytoprotective compounds or cytoprotective proteases. The invention further provides therapeutic use or methods of employing a PAR 1 derived cytoprotective oligopeptide or polypeptide to treat conditions associated with tissue injuries or undesired apoptosis.Type: ApplicationFiled: November 7, 2012Publication date: February 12, 2015Inventors: Laurent O. Mosnier, John H. Griffin
-
Publication number: 20150044166Abstract: Methods, compositions, and medical device systems relating to treating exercise-induced pulmonary hemorrhage (EIPH) and nasopharyngeal cicatrix (NC) in a mammal. For example, one method comprises administering through inhalation a composition comprising a physiologically acceptable carrier and an effective amount of each of one or more stem cell derived factors. Exemplary stem cell derived factors include, but are not limited to, growth factors, chemokines, and cytokines. The mammal may be a horse, dog, camel, or Homo sapiens.Type: ApplicationFiled: August 7, 2014Publication date: February 12, 2015Inventor: Michael Riddle, JR.
-
Publication number: 20150037294Abstract: The present invention provides methods for promoting wound healing and treating muscle atrophy in a mammal in need. The method comprises administering to the mammal a Nell1 protein or a Nell1 nucleic acid molecule.Type: ApplicationFiled: September 25, 2014Publication date: February 5, 2015Inventor: Cymbeline T. Culiat
-
Publication number: 20150037350Abstract: The invention provides means for treating Th1- and Th2-mediated diseases, such as asthma, allergic dermatitis and Th2-driven cancer. The invention extends to pharmaceutical compositions for use in treating such conditions, and to methods of treatment. The invention also extends to adjuvants and vaccines per se, and to their use in enhancing the immunomodulatory activity of immunogens.Type: ApplicationFiled: March 15, 2013Publication date: February 5, 2015Applicant: UCL BUSINESS PLCInventors: Anna L. Furmanski, Jose Ignacio Saldana, Tessa Crompton
-
Publication number: 20150037323Abstract: The present invention refers to monoclonal humanized antibodies, which bind to the extracellular domain of the AXL receptor tyrosine kinase and which at least partially inhibit AXL activity.Type: ApplicationFiled: July 15, 2014Publication date: February 5, 2015Applicant: U3 PHARMA GMBHInventors: Peter WIRTZ, Jens RUHE, Takeshi TAKIZAWA, Tomoko TAKAYAMA
-
Patent number: 8945576Abstract: This invention relates to a vaccine for preventing or treating tautopathy, comprising a vector, as an active ingredient, comprising a nucleic acid encoding a mutant tau protein linked to a secretion signal sequence, wherein the vaccine is capable of inducing an antibody against an (optionally phosphorylated) tau protein in a subject in a more sustained manner compared with a case where the mutant tau protein is administered directly.Type: GrantFiled: January 11, 2011Date of Patent: February 3, 2015Assignees: Kyoto University, National Institute of Radiological SciencesInventors: Haruhisa Inoue, Hiroki Takeuchi, Ryosuke Takahashi, Makoto Higuchi, Bin Ji, Tetsuya Suhara
-
Patent number: 8945529Abstract: A biphasic lipid vesicle composition for treating cervical displasia by intravaginal delivery. The composition includes a suspension of lipid-bilayer vesicles having entrapped therein, an oil-in-water emulsion, human interferon alpha-2b and L-methionine, the composition having an interferon alpha-2b specific activity of between about 1-10 MIU (million international units) per gram composition, and between 0.01 to 0.5 weight percent L-methionine. In the treatment method, the composition is administered at a dose of between about 1-20 MIU interferon alpha-2b, and this dose is administered at least 3 days/week, for a period of at least 4 weeks.Type: GrantFiled: March 27, 2008Date of Patent: February 3, 2015Assignee: Helix BioPharma CorporationInventors: Marianna Foldvari, Praveen Kumar, John M. Docherty
-
Patent number: 8945575Abstract: The methods and compositions described herein are based, in part, on the discovery of a polypeptide of soluble CD23 (sCD23) that binds and sequesters IgE. Thus, the sCD23 peptides, polypeptides and derivatives described herein are useful for treating conditions or disorders involving increased IgE levels such as e.g., allergy, anaphylaxis, inflammation, lymphoma, and certain cancers.Type: GrantFiled: December 1, 2010Date of Patent: February 3, 2015Assignees: Trustees of Boston University, Boston Medical Center CorporationInventors: Lisa Ganley-Leal, John H. Connor
-
Publication number: 20150031624Abstract: The invention provides a chimeric antigen receptor (CAR) (a) an antigen binding domain of HN1 or SS, a transmembrane domain, and an intracellular T cell signaling domain, or (b) an antigen binding domain of SS1, a transmembrane domain, an intracellular T cell signaling domain, and a granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor 2 leader. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.Type: ApplicationFiled: March 5, 2013Publication date: January 29, 2015Inventors: Steven A. Feldman, Steven A. Rosenberg, Ira H. Pastan
-
Publication number: 20150030586Abstract: Compositions and methods for the therapy and diagnosis of cancer are disclosed. For example, illustrative compositions comprise one or more cancer-associated antibodies, polypeptides, polynucleotides, antigen presenting cells, and the like. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly cancer.Type: ApplicationFiled: June 19, 2012Publication date: January 29, 2015Inventors: Sarah Ellen Warren, Carl Weissman
-
Publication number: 20150030611Abstract: Provided are methods and compositions for the modulation of hepatocyte growth factor activity to regulate lymphatic vessel development and function. Methods and composition for the monitoring and treatment of skin disorders, lymphedema, and metastatic cancers are disclosed. Also described are methods of identifying inhibitors of hepatocyte growth factor dependent lymphangiogenesis.Type: ApplicationFiled: October 7, 2014Publication date: January 29, 2015Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Michael Detmar, Kentaro Kajiya
-
Patent number: 8940695Abstract: The present invention provide purified Flt4 receptor tyrosine kinase polypeptides and fragments thereof, polynucleotides encoding such polypeptides, antibodies that specifically bind such polypeptides, and uses therefor.Type: GrantFiled: January 6, 2006Date of Patent: January 27, 2015Assignee: Vegenics Pty LimitedInventors: Kari Alitalo, Taija Makinen
-
Patent number: 8940308Abstract: Disclosed is a method for decreasing depression in a patient by local administration of a botulinum neurotoxin to the frontalis, corrugator, procereus, occipitalis, temporalis, trapezius and cervical paraspinal muscles.Type: GrantFiled: February 1, 2013Date of Patent: January 27, 2015Assignee: Allergan, Inc.Inventors: Catherine C. Turkel, Mitchell F. Brin
-
Publication number: 20150023970Abstract: In certain aspects, the present invention provides compositions and methods for inducing utrophin expression in muscle with an ActRIIB protein as therapy for muscular dystrophy. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand.Type: ApplicationFiled: April 16, 2014Publication date: January 22, 2015Applicant: ACCELERON PHARMA INC.Inventors: Jasbir Seehra, Jennifer Lachey
-
Publication number: 20150023981Abstract: The present invention relates generally to a method of modulating graft functionality. More specifically, the present invention relates to a method of downregulating the onset or progression of graft dysfunction by downregulating the functional level of activin. The method of the present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by graft dysfunction, such as the primary graft dysfunction associated with organ transplantation.Type: ApplicationFiled: May 17, 2013Publication date: January 22, 2015Applicant: PARANTA BIOSCIENCES LIMITEDInventors: David De Kretser, Robyn O'Hehir, Yi Chen
-
Publication number: 20150025022Abstract: Provided are engineered soluble hIL-17RA receptors with high affinity to hIL-17 that inhibit downstream IL17A induced signaling events in cells. Also provided are methods of inhibiting hIL-17A induced secretion of CXCL1 and/or IL-6 in cells, as well as methods of treating inflammation and/or inflammatory disorders in a subject.Type: ApplicationFiled: July 18, 2012Publication date: January 22, 2015Inventors: Amir Aharoni, Marianna Zaretzky
-
Patent number: 8937046Abstract: Provided herein are compositions, including pharmaceutical compositions, and methods for modulating, i.e., stimulating or inhibiting, activity of the alternative complement pathway, and methods of identifying factor H-binding proteins.Type: GrantFiled: September 22, 2009Date of Patent: January 20, 2015Assignee: The Regents of the University of Colorado, a Body CorporateInventors: Joshua M. Thurman, V. Michael Holers
-
Patent number: 8936790Abstract: Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.Type: GrantFiled: April 16, 2013Date of Patent: January 20, 2015Assignee: Allergan, Inc.Inventors: Catherine C. Turkel, Sheena K. Aurora, Mitchell F. Brin
-
Patent number: 8937045Abstract: The invention relates to a stable, pharmaceutically acceptable, aqueous formulation of TNF-binding protein, comprising a TNF-binding protein, a buffer and an isotonicity agent.Type: GrantFiled: February 11, 2004Date of Patent: January 20, 2015Assignee: Ares Trading S.A.Inventors: Fabrizio Samaritani, Alessandra Del Rio, Rita Agostinetto
-
Publication number: 20150018278Abstract: The object of the invention is based on inhibiting specific phosphorylation on Thr248 and/or Thr250 residues of human transcription factor E2F4 to inhibit somatic endoreduplication processes in postmitotic cells which may be associated with various pathological conditions. The invention covers all currently known methods for the specific inhibition of protein phosphorylation (including the expression of mutant forms of E2F4 without Thr residues phosphorylated by p38MAPK) or methods developed in the future that may be applied to Thr-248 and/or Thr-250 residues of human transcription factor E2F4.Type: ApplicationFiled: November 15, 2012Publication date: January 15, 2015Inventor: Jose Maria Frade Lopez
-
Patent number: 8932589Abstract: The present invention is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The Klotho fusion polypeptides of the invention include at least a Klotho protein or an active fragment thereof. In one embodiment, the fusion polypeptide comprises a Klotho polypeptide, a FGF (such as FGF23) and (optionally) a modified Fc fragment. The Fc fragment can, for example, have decreased binding to Fc-gamma-receptor and increased serum half-life. The Klotho fusion proteins are useful in the treatment and prevention of a variety of age-related conditions and metabolic disorders. In another embodiment, the fusion polypeptide comprises a FGF (such as FGF23) and a modified Fc fragment.Type: GrantFiled: March 12, 2013Date of Patent: January 13, 2015Assignee: Novartis AGInventors: David Glass, Shou-Ih Hu
-
Patent number: 8933033Abstract: The invention relates generally to chaperonin 10 N-terminal variants. More specifically, the invention relates to chaperonin 10 N-terminal variants with enhanced immunomodulatory capacity and/or enhanced binding affinity for pathogen-associated molecular patterns (PAMPs) and/or damage-associated molecular patterns (DAMPs).Type: GrantFiled: October 8, 2010Date of Patent: January 13, 2015Assignee: CBio LimitedInventors: Dean Jason Naylor, Richard James Brown, Christopher Bruce Howard, Christopher John De Bakker, Jeanette Elizabeth Stok, Andrew Leigh James, Daniel Scott Lambert, Kylie Jane Ralston, Walter Rene Antonius Van Heumen, Linda Allison Ward
-
Patent number: 8932600Abstract: Modified Rv3616c proteins and their use as medicaments, particularly for the prevention of reactivation of tuberculosis.Type: GrantFiled: January 27, 2011Date of Patent: January 13, 2015Assignees: GlaxoSmithKline Biologicals S.A., Glaxo Group LimitedInventors: Normand Blais, James Brown, Anne-Marie Gelinas, Pascal Mettens, Dennis Murphy
-
Publication number: 20150011482Abstract: Nutritive proteins are provided. In some embodiments the nutritive proteins comprise a first polypeptide sequence comprising a fragment of a naturally-occurring nutritive protein. In some embodiments the fragment comprises at least one of a) an enhanced ratio of branch chain amino acid residues to total amino acid residues present in the nutritive protein; b) an enhanced ratio of leucine residues to total amino acid residues present in the nutritive protein; and c) an enhanced ratio of essential amino acid residues to total amino acid residues present in the nutritive protein.Type: ApplicationFiled: March 15, 2013Publication date: January 8, 2015Inventors: David Arthur Berry, Brett Adam Boghigian, Nathaniel W. Silver, Geoffrey von Maltzahn, Rajeev Chillakuru, Michael Hamill
-
Publication number: 20150010531Abstract: The present invention relates to a method for the treatment of vascular dysfunction, reducing ischemic pain and/or treatment of a vascular disease comprising administering a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof to a patient in need of such treatment. The vascular dysfunction, ischemic pain and/or vascular disease may be associated with impaired endothelium mediated vasodilatation, a reduced eNOS activity, and/or a reduced NO bioavailability. The patient may be suffering from a disease selected from angina pectoris, ischemic heart disease, peripheral artery disease, systolic hypertension, migraine, type 2 diabetes and erectile dysfunction.Type: ApplicationFiled: July 31, 2014Publication date: January 8, 2015Applicant: ANNEXIN PHARMACEUTICALS ABInventors: Johan FROSTEGÅRD, Knut PETTERSSON
-
Publication number: 20150010535Abstract: This application is based, inter alia, on the discovery of a binding interaction between the Hn-33 hemagglutinin polypeptide of the type A Clostridium botulinum neurotoxin complex and synaptosomal proteins, including synaptotagmin II (Syt II). Methods of screening for compounds that modulate, e.g., increase or decrease, this interaction are provided. Also provided are compositions and methods for targeting compounds to neuronal and cancer cells by coupling the compounds to Hn-33 or biologically active Hn-33 variants.Type: ApplicationFiled: May 19, 2014Publication date: January 8, 2015Inventor: Bal Ram Singh